NCT02689518

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Clinical and Genetic Assessment of Treatment Response in Patients With Age-related Macular Degeneration Using Intravitreal Aflibercept Injection

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: University of California, San Diego · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)

Detailed description

Clinical and genetic assessment of treatment response in patients with age-related macular degeneration using intravitreal aflibercept injection. This study seeks to determine if different genetic polymorphisms of vascular endothelial growth factor A (VEGF-A) and HtrA serine peptidase 1(HTRA1) and other genes correlate to the response to intravitreal aflibercept injection therapy.

Conditions

• Macular Degeneration
• Wet Macular Degeneration

Interventions

Type	Name	Description
DRUG	Intravitreal aflibercept injection	Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.

Timeline

• Start date: 2014-04-01
• Primary completion: 2019-11-12
• Completion: 2019-11-12
• First posted: 2016-02-24
• Last updated: 2021-03-25
• Results posted: 2021-03-25

Locations

1 site across 1 country: United States